References
- Miller B A. Cancer statistics review: 1973-1989, National Cancer Institute. NIH Pub No. 92-2789 1992; 17: 1–16
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
- Coiffier B, Lepade E, Brière J, Herbrecht R, Tilly T, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
- Northfelt D W, Martin F J, Working P, Volberding P A, Russel J, Newman M, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyetylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36: 55–63
- Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyetylene-glycol coated liposomes. Cancer Res 1994; 54: 987–992
- Bogner J R, Kronawitter U, Rolinski B, Truebembach K, Goebel F D. Liposomial doxorubicin in the treatment of advanced AIDS related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994; 7: 463–468
- Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995; 13: 914–920
- James N D, Coker R J, Tomlinson D, Harris J R, Gompels M, Pinching A J, et al. Liposomal doxorubicin: an effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol 1994; 6: 294–296
- Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's Sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711–716
- Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol 2001; 127: 128–134
- Aviles A, Neri N, Castaneda C, Talavera A, Huerta-Guzman J, Gonzalez M. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol 2002; 19: 55–58
- Chanan-Khan A, Islam T, Bernstein S H. CDOP (cyclophosphamide, doxil, vincristine, prednisone) as a front-line regimen for elderly patients with intermediate grade non-Hodgkin's lymphoma (IG-NHL). Blood 2001; 98: 4681a
- Martino R, Perea G, Caballero M D, Mateos M V, Ribera J M, de Oteyza J P, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002; 87: 822–827
- Tsavaris N, Kosmas C, Vadiaka M, Giannouli S, Siakantaris M P, Vassilakopoulos T, et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res 2002; 22: 1845–1848
- Tulpule A, Khan A U, Mohrbacher A F. A phase II trial of pegylated liposomal doxorobucin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non Hodgkin's lymphoma. ASCO 2004; 23: 6688a
- Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European – American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
- Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
- Kaplan J O, Meier P. Non parametic estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481
- Lipshultz S E, Grenier M A, Colan S D. Doxorubicin-induced cardiomyopathy. N Engl J Med 1999; 340: 653–655
- Sparano J A, Wolff A C, Brown D. Troponins for predicting cardiotoxicity from cancer therapy. Lancet 2000; 356: 1947–1948
- Auner H W, Tinchon C, Quehenberger F, Linkesch W, Sill H. Troponins in prediction of cardiotoxic effects. Lancet 2001; 357: 808
- Cardinale D, Sandri M T, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–522